上海科技大学免疫化学研究所今揭牌 Shanghai university of science and technology institute of immune chemical this celebration? ?? ?

　　本报上海10月14日电（记者曹继军、颜维琦）免疫化学是最前沿的治疗性抗体研究的基础，是当今和未来新药研发中的重要领域。上海科技大学免疫化学研究所日前在沪揭牌。该所由上海科技大学（筹）和中国科学院上海高等研究院共建，致力于打造基础研究和临床应用相结合、医学研究和生物技术产业相结合的多功能交叉基地、创新型生物医药产业和免疫化学高端人才培养的研发基地，同时带动治疗性抗体的研发，形成治疗性抗体的产业化。

Our newspaper Shanghai October 14 dec(Reporter CaoJiJun/YanWeiQi)Immune chemistry is the cutting edge of the therapeutic antibodies the basis of study,Is today and future in new drug research and important fields.Shanghai university of science and technology institute of immune chemical in Shanghai has approved.Along by the Shanghai university of science and technology(raise)And the Chinese academy of sciences institute of Shanghai higher build,Devote oneself to to make the basic research and clinical application of combination/Medical research and the biotechnology industry combination of multi-function cross base/Innovative biological medicine industry and immunochemical high-end talent cultivation research and development base,At the same time, promote the development of therapeutic antibodies,Formation of the industrialization of the therapeutic antibodies.

　　据了解，上海科技大学免疫化学研究所实行理事会领导下的所长负责制，首任所长Richard A·Lerner（理查德·乐纳）教授是国际著名生物技术研究机构美国Scripps研究所前所长，是美国国家科学院、医学科学院及艺术与科学院三院院士。作为免疫化学理论的奠基人和先驱，他的实验室开发出了几乎所有重要的免疫化学研究方法，包括组合抗体库技术、催化抗体技术和细胞内组合抗体库技术等。研究所将针对各项人类重大疾病开展人源细胞表面的免疫抗原图谱的制作，构建高效重组人源抗体库、筛选可用于临床治疗的新型单克隆抗体和药物靶点，并建立抗体的体外重组和优化技术平台。

It is understood,Shanghai university of science and technology institute of immune chemical a council under the leadership of the director responsibility system,First director Richard a. Lerner(Richard's music)Professor is a famous international biological technology research institute the Scripps research institute of before,Is the United States national academy of sciences/Academy of medical sciences and arts and academy of sciences academician twenty.As the founder of the immune chemical theory and pioneer,His laboratory developed almost all of the important immune chemical research methods,Including combination antibody library technology/Catalytic antibody technique and intracellular combination antibody library technology, etc.The institute of all human major disease to carry out humanized cell surface immune antigen map production,Construction of the highly restructuring humanized antibody library/Screening can be used in the clinical treatment of new type of monoclonal antibody and drug targets,And to establish antibody in vitro restructuring and optimization technology platform.